Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Erasca (ERAS – Research Report) today and set a price target of $64.00. The company’s shares opened today at $1.97.
Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Xencor, and Krystal Biotech. According to TipRanks, Stranahan has an average return of 3.6% and a 54.76% success rate on recommended stocks.
Currently, the analyst consensus on Erasca is a Strong Buy with an average price target of $7.50.
The company has a one-year high of $3.38 and a one-year low of $1.51. Currently, Erasca has an average volume of 794.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Erasca (ERAS) Company Description:
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
Read More on ERAS:
- Erasca reports Q1 EPS (23c), consensus (20c)
- Erasca Reports First Quarter 2024 Business Updates and Financial Results
- Erasca Secures Funding for Future Growth Through Private Placement
- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca reports Q4 EPS (20c), consensus (23c)
